Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient

European Journal of Haematology

Volumn 66, Issue 4, 2001, Pages 263-271

  Rabizadeh, E ^b   Bairey, O ^b   Aviram, A ^b   Ben Dror, I ^b   Shaklai, M ^b   Zimra, Y ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b NONE

Author keywords

AN 9; B chronic lymphocytic leukemia; Bax; bcl 2; Doxorubicin

Indexed keywords

ACRIDINE ORANGE; BUTYRIC ACID DERIVATIVE; DOXORUBICIN; IDARUBICIN; PIVALOYLOXYMETHYL BUTYRATE; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; BUTYRATES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0035010514     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.066004263.x     Document Type: Article

References (38)

1. 1. GORCZYCA W, GONG J, ARDELT B, TRAG F, DARZYNKIEWICZ Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993;53:3186-3192.
2. 2. TSUJIMOTO Y, GORHAM J, COSSMAN J, JASFFE E, CROCE CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-1393.
3. 3. REED JC. Double identity for proteins of the bcl-2 family. Nature 1997;387:773-776.
4. 4. YANG E, KORSMEYER SJ. Molecular apoptosis: A discourse on the bcl-2 family and cell death. Blood 1996;88:386-401.
5. 5. GALE RP, CALIGARIS-CAPPIO F, DIGHIERO G, KEATING M, MONTSERRAT E, RAI K. Recent progress in chronic lymphocytic leukemia. Leukemia 1994;8:1610-1614.
6. 6. REED JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998;25:11-18.
7. 7. SCHENDEL SL, XIE Z, MONTAL MO. Channel formation by antiapoptotic protein bcl-2. Proc Natl Acad Sci USA 1997;94:5113-5118.
8. 8. OLTVAI Z, MILLIMAN CL, KORSMEYER SJ. Bcl-2 heterodimerizes in vivo with conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-619.
9. 9. THOMAS A, EL ROUBY S, REED JC, KRAJEEWSKI S, SILBER R, POTMESIL M, NEWCOMB EW. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-1062.
10. 10. PRASAD KN. Butyric acid: a small fatty acid with diverse biological functions. Life Sci 1980;27:1351-1358.
11. 11. REPHAELI A, RABIZADEH E, AVIRAM A, SHAKLAI M, RUSE M, NUDELMAN A. Derivatives of butyric acid as potential antineoplastic agents. Int J Cancer 1991;49:66-72.
12. 12. MILLER AA, KURSCHEL E, OSIEKA R, SCHMID T. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987;23:1283-1287.
13. 13. BUNDGAARD H, NIELSEN NM. Esters of N,N-disubstituted 2-hydroxyacetamides as novel highly biolabile prodrug types for carboxylic acid agents. J Med Chem 1987;30:451-455.
14. 14. NUDELMAN A, RUSE M, AVIRAM A, et al. Novel anticancer prodrugs of butyric acid. J Med Chem 1992;35:687-694.
15. 15. RABIZADEH E, SHAKLAI M, NUDELMAN A, EISENBACH L, REPHAELI A. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. Febs Lett 1993;328:225-229.
16. 16. ZIMRA Y, WASSERMAN L, MARON L, SHAKLAI M, NUDELMAN A, REPHAELI A. Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. J Cancer Res Clin Oncol 1997;123:152-160.
17. 17. ROZMAN C, MONTSERRAT E. Chronic lymphocytic leukemia. Engl J Med 1995;333:1052-1056.
18. 18. BINET JL, AUQUIER A, DIGHIERO G, et al. New prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
19. 19. NICOLETTI I, MIGLIORATI A, PAGLIACCI MI, GRINGHANI F, RICCADI CJ. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Immunol Meth 1991;139:271-279.
20. 20. HARE JD, BAHLER DW. Analysis of plasmodium falciparum growth in culture using acridine orange and flow cytometry. J Histol Cytol 1986;34:215-220.
21. 21. POUILLART PR. Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life Sci 1998;63:1739-1760.
22. 22. LIU WH, YUNG BY. Mortalization of human promyelocytic leukemia HL-60 cells to be more susceptible to sodium butyrate induced apoptosis and inhibition of telomerase activity by down regulation of nucleophosmin/B23. Oncogene 1998;17:3055-3064.
23. 23. YAMAMOTO H, FUJIMOTO J, OKAMOTO E, et al. Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer 1998;76:897-902.
24. 24. HAGUE A, MANNING AM, HANLON KA, HUSCHTSCHA LI, HART D, PARASKEVA C. Sodium butyrate induces apoptosis in human colonic tumor cell lines in a p53-independent pathway: Implications for the possible role of dietary fibers in the prevention of large-bowel cancer. Int J Cancer 1993;55:498-505.
25. 25. CALABRESSE C, VENTURINI L, RONCO G, et al. Selective induction of apoptosis in myeloid leukemic cell lines by monoacetone glucose-3 butyrate. Biochem Biophys Res Commun 1994;201:266-283.
26. 26. HAGUE A, DARIODIAZ G, HICKS DJ, KRAJEWSKI S, REED JC, PARASKEVA C. Bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells: however overexpression of bcl-2 does not protect against bak-mediated apoptosis. Int J Cancer 1997;72:898-905.
27. 27. AGULAR-SANTELISES M, ROTTENBERG ME, LEWINE N, MELLSTEDT H, JONDAL M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 1996;69:114-119.
28. 28. PEPPER C, BENTLEY P, HOY T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukemia. Br J Haemtol 1996;95: 513-517.
29. 29. PEPPER C, THOMAS A, HOY T, BENTLEY P. Chlorambucil resistance in B-cell chronic lymphocytic leukemia is mediated through failed Bax induction and selection of high BCL-2 expressing subclones. Br J Haematol 1999;104:581-588.
30. 30. AVIRAM A, RABIZADEH E, ZIMRA Y, et al. Expression of Bcl-2 and Bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease. Eur J Haematol 2000;63:1-5.
31. 31. KITADA S, ANDERSEN J, AKAR S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlation with in vitro and in vivo chemoresponses. Blood 1998;91:3379-3389.
32. 32. ROBERTSON LE, PLUNKETT W, MCCONNEL K, KEATING MJ, MCDONNELL TJ. Leukemia 1996;10:456-459.
33. 33. AVIRAM A, REPHAELI A, SHAKLAI M, et al. Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. J Cancer Res Clin Oncol 1997;123:267-271.
34. 34. WAHLFORS J, HILTUNEN H, HEINONEN K, HAMALAINEN E, ALHONEN L, JANNE J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 1992;80:2074-2080.
35. 35. HANADA M, DELIA D, AIELLO A, STADTMAUER E, REED JC. bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82: 1820-1828.
36. 36. VIDALI G, BOFFA LC, BRADBURY EM, ALLFREY FG. Butyrate suppression of histone deacetylation leads to accumulation of poly-acetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci (Wash) 1978;75: 2239-2243.
37. 37. AVIRAM A, ZIMRA Y, NUDELMAN A, REPHAELI A, SHAKLAI M. Comparison between the effect of butyric acid and its prodrug on histones hyperacethylation in HL-60 leukemic cell line. Int J Cancer 1994;56:906-909.
38. 38. KASUKABE T, REPHAELI A, HONMA Y. An anti-cancer derivative of butyric acid (pivaloyloxymethyl butyrate) and daunorubicin cooperatively prolong the survival of mice inoculated with monocytic leukemia. Br J Cancer 1997;75:850-854.